Quick summary: Psychedelic-assisted therapy has shown real promise in easing the anxiety, depression and hopelessness that many terminally ill patients face, but researchers warn that almost all the evidence behind it comes from Western clinical settings. Using Chinese palliative care as an example, they show how family centred decision making, spiritual beliefs and attitudes towards duty and the afterlife can shape how patients experience these treatments, sometimes easing distress and sometimes deepening it. For healthcare providers and policymakers expanding access to psychedelic therapy, the message is that cultural humility, not a single standard protocol, will be essential to delivering safe and meaningful care towards the end of life.
For people facing a terminal diagnosis, the fear and despair that can accompany dying are often harder to treat than physical pain. A new commentary published in Translational Psychiatry suggests that psychedelic assisted therapy, already shown to ease this kind of existential distress, may not work the same way for everyone, because it has been developed almost entirely within Western cultural settings.
The paper, led by researchers from the University of Hong Kong, reviews decades of clinical trials using psilocybin and LSD alongside psychotherapy for patients with life limiting illness, mostly cancer. Studies from institutions including Johns Hopkins and New York University found that a single guided psychedelic session could bring lasting reductions in anxiety, depression and hopelessness, with benefits recorded years later in some patients.
But the authors argue that almost all of this research reflects Euro American assumptions about what makes a death “good”. They use Chinese palliative care as a case study, pointing out that decisions there are often shared among family members rather than made solely by the patient, and that concepts drawn from Confucianism, Buddhism, Daoism and folk belief shape how people understand suffering, duty and the afterlife.
This matters because psychedelics do not act in isolation. Their effects depend heavily on what researchers call set and setting, meaning a person’s mindset going in and the environment around them. A patient’s cultural background can therefore influence how they interpret visions, emotional breakthroughs or feelings of connection to ancestors during a session, sometimes deepening comfort and sometimes intensifying guilt or distress.
The researchers propose a framework called cultural humility, a concept that asks clinicians to approach each patient as a source of knowledge rather than assuming their own training covers every worldview. In practice, this could mean involving family members or spiritual advisors in preparation and aftercare, adapting the physical environment with culturally meaningful objects or music, and being alert to how family centred decision making might shape what a patient wants to share.
The commentary arrives as interest in psychedelic assisted therapy continues to grow worldwide. Australia became the first country to allow psilocybin and MDMA to be prescribed for certain conditions in 2023, and regulators in the United States, Germany, New Zealand and elsewhere are exploring similar pathways. As access expands beyond the hospitals where the original trials took place, the authors warn that treatment protocols built for one cultural context may not translate smoothly to another.
Their broader point is that easing existential distress at the end of life is not purely a matter of brain chemistry. It is also a deeply human and cultural process, shaped by family, belief and tradition, and the researchers say future trials and clinical guidelines need to reflect that diversity rather than treating a single model as universal.
